616459

TGF-β RI Kinase Inhibitor VIII

The TGF-β RI Kinase Inhibitor VIII, also referenced under CAS 356559-20-1, controls the biological activity of TGF-β RI Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• 別名: TGF-β RI Kinase Inhibitor VIII, ALK5 Inhibitor VIII, SB-525334, 6-(2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl)-quinoxaline, Transforming Growth Factor-β Type I Receptor Kinase Inhibitor VIII
• 実験式（ヒル表記法）: C₂₁H₂₁N₅
• CAS番号: 356559-20-1
• 分子量: 343.42
• MDL番号: MFCD11045307
• UNSPSCコード: 12352200

特性

• 品質水準: 100
• アッセイ: ≥97% (HPLC)
• 形状: solid
• メーカー／製品名: Calbiochem^®
• 保管条件: OK to freeze; protect from light
• 色: yellow
• 溶解性: DMSO: 10 mg/mL
• 輸送温度: ambient
• 保管温度: 2-8°C
• InChI: 1S/C21H21N5/c1-13-6-5-7-16(24-13)19-18(25-20(26-19)21(2,3)4)14-8-9-15-17(12-14)23-11-10-22-15/h5-12H,1-4H3,(H,25,26)
• InChI Key: DKPQHFZUICCZHF-UHFFFAOYSA-N

詳細

詳細

A cell-permeable quinoxaline compound that acts as a potent, highly selective, ATP-competitive inhibitor against type I TGF-β receptor TβR-I/ALK5 (IC₅₀ = 14.3 nM), while exhibiting 4-fold less potency toward ALK4 (IC₅₀ = 58.5 nM) and little or no activity against ALK2/3/6 and a panel of 26 other commonly studied kinases (≤29% inhibition at 10 µM). Effectively blocks (by >95%) TGF-β1-induced Smad2/3 activation (2 µM in ELT-3 cultures) and nuclear localization (1 µM in RPTE cultures), as well as TGF-β1-dependent p3TP- and ARE-luciferase transcription (0.1 µM in HaCat cultures). SB-525334 is orally available and is shown to attenuate Bleomycin- and Puromycin-induced tissue fibrosis in mice and rats in vivo.

包装

Packaged under inert gas

警告

Toxicity: Harmful (C)

再構成

Following reconstitution, aliquot and freeze (-20&deg:C). Stock solution is stable for up to 3 months at -20°C.

その他情報

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Higashiyama, H., et al. 2007. Exp. Mol. Pathol.83, 39.
Grygielko, E.T., et al. 2005. J. Pharmacol. Exp. Ther.313, 943.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3